Synchrogenix Appoints Two New Global Submissions Directors

Synchrogenix Appoints Two New Global Submissions Directors

WILMINGTON, Del., Oct. 23, 2014 /PRNewswire/ -- Synchrogenix Information Strategies Inc., a regulatory writing company headquartered in Wilmington, Delaware, is pleased to announce the addition of two new Global Submissions Directors; Kelley Hill; Cambridge, Massachusetts; and Aaron Bernstein; Bloomfield, New Jersey.

Synchrogenix, A Certara Company, provides global regulatory writing services to the pharmaceutical, biotechnology, and medical device industry worldwide.
Kelley Hill brings over 16 years of pharmaceutical experience in drug development to Synchrogenix. Ms. Hill's experience extends from target identification through regulatory submissions and post-marketing activities with particular expertise in rare diseases, orphan drugs, and oncology. Most recently, she has been responsible for managing the medical and regulatory writing activities for multiple projects across 10 development programs. Additionally, Ms. Hill has accrued 16 years in academic experience across the life sciences.

Dr. Aaron Bernstein is a regulatory writing and business analyst expert with over 20 years of experience. Dr. Bernstein has been instrumental in developing and leading writing teams for the submission of clinical and regulatory documents to Health Authorities worldwide. His therapeutic expertise includes metabolic diseases, HIV/AIDS, and cardiology. He will be joining Synchrogenix to pioneer the new office location in Bloomfield, New Jersey.

"Kelley and Aaron are highly respected leaders and recognized mentors in our industry," said Ellen Barrosse, CEO and founder of Synchrogenix. "I am very excited to add their expertise to the exceptional team we've built."

About Synchrogenix, a Certara Company

Synchrogenix, a Certara company, encompasses a group of separate entities operating together to provide regulatory writing services to the pharmaceutical, biotech, and medical device industry worldwide. Synchrogenix Information Strategies Inc.; SynchroWest, Inc.; Synchrogenix Europe, Ltd.; and Synchrogenix Philippines, Inc., (SPI) are all wholly owned subsidiaries with an overall governance structure that creates and enforces a global standard of service, technology, and quality.

Logo -

SOURCE Synchrogenix Information Strategies Inc.

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.